Identification and Therapeutic Intervention of Co ‐activated ALK, FGFR2 and EphA5 Kinases in Hepatocellular Carcinoma

Conclusion: Our findings revealed a paradigm that highlights the cooperation of ALK, FGFR2 and EphA5 kinases in governing growth advantage of HCC cells, which might offer a novel conceptual “combined therapeutic target” for diagnosis and subsequent intervention in subgroup of HCC patients. This article is protected by copyright. All rights reserved.

Source: Hepatology - January 21, 2018 Category: Internal Medicine Authors: Xin Wang, Minmin Zhang, Fangfang Ping, Hongchun Liu, Jingya Sun, Yueqin Wang, Aijun Shen, Jian Ding, Meiyu Geng Tags: Hepatobiliary Malignancies Source Type: research